Grant Papanek Julie's Form 4 filing
Day One Biopharmaceuticals, Inc. (DAWN) · filed Jul 6, 2022
- Accession no.
- 0001209191-22-041408
- Filed
- Jul 6, 2022
- Trade date
- Jul 1-5, 2022
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market sales total $36.0K. It was filed 5 days after the trade.
This filing was later replaced by the amendment 0001209191-22-041994 (Jul 12, 2022). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Grant Papanek JulieCIK 0001673237 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 1, 2022 | Common Stock | SSaleDisposed | −1,000 | $20.00 | −$20,000 | 464,000 | Indirect | |
| Jul 5, 2022 | Common Stock | SSaleDisposed | −800 | $20.00 | −$16,000 | 463,200 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.